LIVN vs NRXP
LIVN: LivaNova is a medical technology company specializing in innovative cardiovascular and neuromodulation therapies to improve patient lives. NRXP: Clinical-stage biotech developing ketamine and NMDA receptor-modulating drugs for treatment-resistant depression, PTSD, and suicidal ideation with three candidates in late-stage FDA review.
Side-by-side fundamentals
| Metric | LIVN | NRXP | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $80.58 | $3.63 | |
| Market cap as of 2026-07-29 | $4.5B | $148M | |
| P/E as of 2026-07-29 | 41.40 | n/a | |
| PEG as of 2026-07-29 | 3.92 | n/a | |
| Net margin as of 2026-07-29 | +7.5% | -2336.5% | LIVN higher |
| Gross margin as of 2026-07-29 | +67.5% | +58.8% | LIVN higher |
| Operating margin as of 2026-07-29 | +13.1% | -1830.6% | LIVN higher |
| ROE as of 2026-07-29 | +9.1% | -195.8% | LIVN higher |
| ROA as of 2026-07-29 | +4.2% | -219.6% | LIVN higher |
| Debt / equity as of 2026-07-29 | 0.24 | 1.42 | LIVN lower |
| Revenue growth (YoY) as of 2026-07-29 | +12.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +10.8% | n/a | |
| Beta as of 2026-07-29 | 0.88 | 2.16 | |
| 1-year return as of 2026-07-27 close | +84.5% | +21.0% | LIVN higher |
Fundamentals: market data, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.